抗PD-1/PD-L1抗体单药及联合治疗晚期胆道癌相关不良反应管理进展

The adverse events management of anti-PD-1/PD-L1 antibody monotherapy and combination therapy in the treatment of advanced biliary tract cancer

摘要: 抗程序性死亡受体1（PD-1）及其配体（PD-L1）抗体已应用于临床多种肿瘤的治疗，在晚期胆道癌（biliary tract cancer，BTC）也取得显著疗效，但同时也有导致多种不良反应（adverse effects, AEs），如皮疹、腹泻及肝功能损伤等。本文对抗PD-1/PD-L1抗体单药及联药治疗BTC的疗效、相关AEs及管理对策作一综述。

Abstract: Anti-programmed death receptor 1 (PD-1) and its ligand (PD-L1) antibodies have been applied in the clinical treatment of a variety of tumors, including advanced biliary tract cancer (BTC), and have achieved significant efficacy. Meanwhile, PD-1/PD-L1 antibodies also result in many adverse effects (AEs), such as rush, diarrhea, liver dysfunction and so on. This paper briefly reviews efficacy and AEs of anti-PD-1/PD-L1 antibodies monotherapy and combination therapy in BTC, and tries to formulate strategies of AEs management.